论文信息 - FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study† - 字舞流文

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study†

J. Sakamoto | H. Baba | K. Oba | T. Shimoyama | T. Denda | M. Inukai | H. Tamagawa | T. Hata | T. Kato | H. Mishima | S. Iwamoto | K. Ina | Y. Munemoto | N. Nagata | K. Kurachi | M. Nakamura | Y. Morita | M. Ooshiro | K. Kunieda | T. Takahashi | T. Takahashi